Published in Europace on February 13, 2013
Prevention of Stroke and Systemic Embolic Events in Patients With Atrial Fibrillation | NCT00684307
Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation - a nationwide cohort study. BMC Health Serv Res (2017) 1.38
A population database study of outcomes associated with vitamin K antagonists in atrial fibrillation before DOAC. Br J Clin Pharmacol (2015) 0.78
Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. Sci Rep (2016) 0.77
Compliance and adherence to oral anticoagulation therapy in elderly patients with atrial fibrillation in the era of direct oral anticoagulants. J Geriatr Cardiol (2016) 0.75
Stroke And Bleeding Risk Assessment: Where Are We Now? J Atr Fibrillation (2014) 0.75
Bleeding risk during oral anticoagulation therapy for atrial fibrillation. Europace (2013) 0.75
Anticoagulation in pulmonary arterial hypertension: Contemporary data from COMPERA registry. Glob Cardiol Sci Pract (2014) 0.75
Thromboembolism and bleeding risk scores and predictors of cardiac death in a population with atrial fibrillation. Arq Bras Cardiol (2017) 0.75
Bleeding-related admissions in patients with atrial fibrillation receiving antithrombotic therapy: results from the Tasmanian Atrial Fibrillation (TAF) study. Eur J Clin Pharmacol (2017) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest (2010) 10.29
Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet (1989) 10.18
Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med (2011) 8.75
Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation (2007) 5.89
Probability of adverse events that have not yet occurred: a statistical reminder. BMJ (1995) 5.55
Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet (1994) 5.37
Stroke and bleeding in atrial fibrillation with chronic kidney disease. N Engl J Med (2012) 4.69
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med (2010) 4.01
Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J (2012) 3.66
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA (2005) 3.54
Effect of study setting on anticoagulation control: a systematic review and metaregression. Chest (2006) 2.79
Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. Circulation (2011) 2.60
Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol (2004) 2.60
Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med (2007) 2.16
Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost (2008) 2.05
Gains and losses of warfarin therapy as performed in an anticoagulation clinic. J Intern Med (2006) 2.02
Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost (2011) 2.01
Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation. Arch Intern Med (2001) 1.82
Rates of hemorrhage during warfarin therapy for atrial fibrillation. CMAJ (2012) 1.68
Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J (2011) 1.67
Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis. Ann Pharmacother (2011) 1.61
Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol (2009) 1.58
Culprit factors for the failure of well-conducted warfarin therapy to prevent ischemic events in patients with atrial fibrillation: the role of homocysteine. Stroke (2005) 1.49
Thromboembolic prophylaxis in nonrheumatic atrial fibrillation: utilization patterns, efficacy, and complications in a long-term follow-up of community patients. Int J Cardiol (2004) 1.45
Dronedarone and vitamin K antagonists: a review of drug-drug interactions. Am Heart J (2010) 1.43
Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke (2010) 1.33
Combined anticoagulant-antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke (2004) 1.23
Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. Curr Med Res Opin (2005) 1.22
Incidence of major bleeding complication of warfarin therapy in Japanese patients with atrial fibrillation. Circ J (2007) 1.10
The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. J Clin Epidemiol (1989) 1.08
Oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and risk of bleeding. A Multicenter Inception Cohort Study. Thromb Haemost (2001) 1.02
Application of a decision support tool for anticoagulation in patients with non-valvular atrial fibrillation. J Gen Intern Med (2008) 1.01
Bleeding and stroke risk in a real-world prospective primary prevention cohort of patients with atrial fibrillation. Chest (2011) 0.98
Recent developments in atrial fibrillation. BMJ (2005) 0.97
Update on atrial fibrillation: part I. Clin Cardiol (2008) 0.97
Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice. Intern Med J (2001) 0.92
A longitudinal population-based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990-1999. J Thromb Haemost (2006) 0.90
[The randomized study of efficiency and safety of antithrombotic therapy in nonvalvular atrial fibrillation: warfarin compared with aspirin]. Zhonghua Xin Xue Guan Bing Za Zhi (2006) 0.90
Warfarin exposure and the risk of thromboembolic and major bleeding events among medicaid patients with atrial fibrillation. Ann Pharmacother (2006) 0.89
Results of an open-label, prospective study of anticoagulant therapy for atrial fibrillation in an outpatient anticoagulation clinic. Clin Ther (2004) 0.89
Warfarin for non-rheumatic atrial fibrillation: five year experience in a district general hospital. Heart (2004) 0.85
Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population. Curr Med Res Opin (2005) 0.85
Quality of anticoagulation monitoring in nonvalvular atrial fibrillation patients: comparison of anticoagulation clinic versus usual care. Ann Pharmacother (2007) 0.84
The lowest effective intensity of prophylactic anticoagulation for patients with atrial fibrillation. Cerebrovasc Dis (2005) 0.83
Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: a single-center observational study. Thromb Res (2011) 0.81
Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial fibrillation and hypertension. J Hum Hypertens (2010) 0.81
Cost considerations in the management of atrial fibrillation - impact of dronedarone. Clinicoecon Outcomes Res (2012) 0.77
New possibilities in anticoagulant management of atrial fibrillation. Rev Cardiovasc Med (2004) 0.77
Sexual problems and distress in United States women: prevalence and correlates. Obstet Gynecol (2008) 3.41
Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries. Value Health (2005) 2.32
Meta-analysis of early excision of burns. Burns (2006) 2.02
Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest (2006) 1.75
A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in adult and pediatric patients. Biol Blood Marrow Transplant (2007) 1.56
Prescribing patterns of antidepressants in Europe: results from the Factors Influencing Depression Endpoints Research (FINDER) study. Eur Psychiatry (2008) 1.49
Development and validation of a patient satisfaction and preference questionnaire for inhalation devices. Treat Respir Med (2005) 1.25
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost (2014) 1.22
Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain. Eur J Health Econ (2007) 1.13
Capsular contracture in subglandular breast augmentation with textured versus smooth breast implants: a systematic review. Plast Reconstr Surg (2006) 1.10
Meta-analysis comparing total hip arthroplasty with hemiarthroplasty in the treatment of displaced neck of femur fracture. J Arthroplasty (2008) 1.10
Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. Thromb Haemost (2010) 1.06
Help-seeking behavior of women with self-reported distressing sexual problems. J Womens Health (Larchmt) (2009) 1.03
Correlates of sexually related personal distress in women with low sexual desire. J Sex Med (2009) 1.03
Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. Am Heart J (2009) 1.00
Thromboprophylaxis in patients older than 75 years or with moderate renal impairment undergoing knee or hip replacement surgery [corrected]. Int Orthop (2011) 0.98
Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER. J Affect Disord (2008) 0.98
Patient outcomes using the European label for dabigatran. A post-hoc analysis from the RE-LY database. Thromb Haemost (2013) 0.95
Proposing a standardized method for evaluating patient report of the intensity of dyspnea during exercise testing in COPD. Int J Chron Obstruct Pulmon Dis (2012) 0.94
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. J Am Coll Cardiol (2012) 0.93
Effects of preemptive epidural analgesia on post-thoracotomy pain. J Cardiothorac Vasc Anesth (2005) 0.92
Carbetocin for preventing postpartum haemorrhage. Cochrane Database Syst Rev (2012) 0.92
Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Thromb Haemost (2012) 0.90
A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities. J Eval Clin Pract (2010) 0.88
Factors influencing depression endpoints research (FINDER): study design and population characteristics. Eur Psychiatry (2007) 0.88
Respiratory Syncytial Virus Hospitalizations in Healthy Preterm Infants: Systematic Review. Pediatr Infect Dis J (2016) 0.87
Distressing sexual problems in United States women revisited: prevalence after accounting for depression. J Clin Psychiatry (2009) 0.84
Is the EQ-5D responsive to recovery from a moderate COPD exacerbation? Respir Med (2011) 0.82
Progestational agents for treating threatened or established preterm labour. Cochrane Database Syst Rev (2010) 0.82
Cost effectiveness of tiotropium for chronic obstructive pulmonary disease: a systematic review of the evidence. J Med Econ (2010) 0.82
Should a benzodiazepine antagonist be used in unconscious patients presenting to the emergency department? Resuscitation (2007) 0.82
Dabigatran is effective with a favourable safety profile in normal and overweight patients undergoing major orthopaedic surgery: a pooled analysis. Thromb Res (2012) 0.82
Carbetocin for preventing postpartum haemorrhage. Cochrane Database Syst Rev (2012) 0.81
A systematic review of the function and complications of colonic pouches. Int J Colorectal Dis (2006) 0.80
Use of tissue sealants in face-lifts: a metaanalysis. Aesthetic Plast Surg (2008) 0.80
Adjusting for COPD severity in database research: developing and validating an algorithm. Int J Chron Obstruct Pulmon Dis (2011) 0.78
Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding. Thromb Haemost (2012) 0.77
Progestational agents for treating threatened or established preterm labour. Cochrane Database Syst Rev (2014) 0.77
Characteristics of female outpatients with urinary incontinence participating in a 6-month observational study in 14 European countries. Maturitas (2005) 0.77
Cost-effectiveness of tiotropium versus salmeterol: the POET-COPD trial. Eur Respir J (2012) 0.77
Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions? Ann Med (2014) 0.77
A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillation. Pharmacoeconomics (2013) 0.76
A review of tazarotene in the treatment of photodamaged skin. Clin Interv Aging (2008) 0.76
Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines. Pharmacoeconomics (2014) 0.75
Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review. Pharmacoeconomics (2010) 0.75